136 related articles for article (PubMed ID: 23620531)
21. Differences between the United States and Japan in labels of oncological drugs.
Jayaputra K; Ono S
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):143-151. PubMed ID: 27670850
[TBL] [Abstract][Full Text] [Related]
22. Written medicine information from English-speaking countries--how does it compare?
Luk A; Tasker N; Raynor DK; Aslani P
Ann Pharmacother; 2010 Feb; 44(2):285-94. PubMed ID: 20103613
[TBL] [Abstract][Full Text] [Related]
23. Adverse drug reactions in childhood: a review of prospective studies and safety alerts.
Clavenna A; Bonati M
Arch Dis Child; 2009 Sep; 94(9):724-8. PubMed ID: 19531524
[TBL] [Abstract][Full Text] [Related]
24. Safety information in drug labeling: a comparison of the USA, the UK, and Japan.
Shimazawa R; Ikeda M
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):306-18. PubMed ID: 23355452
[TBL] [Abstract][Full Text] [Related]
25. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
Matlock A; Allan N; Wills B; Kang C; Leikin JB
Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
[TBL] [Abstract][Full Text] [Related]
26. Timing of new black box warnings and withdrawals for prescription medications.
Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
[TBL] [Abstract][Full Text] [Related]
27. Consumer understanding of prescription drug information: an illustration using an antidepressant medication.
Shiffman S; Gerlach KK; Sembower MA; Rohay JM
Ann Pharmacother; 2011 Apr; 45(4):452-8. PubMed ID: 21427296
[TBL] [Abstract][Full Text] [Related]
28. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
29. The impact of wording in "Dear doctor" letters and in black box labels.
Weatherby LB; Nordstrom BL; Fife D; Walker AM
Clin Pharmacol Ther; 2002 Dec; 72(6):735-42. PubMed ID: 12496755
[TBL] [Abstract][Full Text] [Related]
30. Boxed warning inconsistencies between drug information resources and the prescribing information.
Cheng CM; Fu C; Guglielmo BJ; Auerbach AD
Am J Health Syst Pharm; 2011 Sep; 68(17):1626-31. PubMed ID: 21856808
[TBL] [Abstract][Full Text] [Related]
31. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
32. The Value of the Black Box Warning in Dermatology.
Winterfield L; Vleugels RA; Park KK
J Drugs Dermatol; 2015 Jul; 14(7):660-6. PubMed ID: 26151780
[TBL] [Abstract][Full Text] [Related]
33. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden.
Ufer M; Kimland E; Bergman U
Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):147-52. PubMed ID: 15072113
[TBL] [Abstract][Full Text] [Related]
34. Adherence to black box warnings for prescription medications in outpatients.
Lasser KE; Seger DL; Yu DT; Karson AS; Fiskio JM; Seger AC; Shah NR; Gandhi TK; Rothschild JM; Bates DW
Arch Intern Med; 2006 Feb; 166(3):338-44. PubMed ID: 16476875
[TBL] [Abstract][Full Text] [Related]
35. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
[TBL] [Abstract][Full Text] [Related]
36. International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.
Song YK; Han N; Burckart GJ; Oh JM
Clin Pharmacol Ther; 2020 Mar; 107(3):530-540. PubMed ID: 31544241
[TBL] [Abstract][Full Text] [Related]
37. Adverse drug reactions in elderly hospitalized patients: a 12-year population-based retrospective cohort study.
Sikdar KC; Dowden J; Alaghehbandan R; MacDonald D; Peter P; Gadag V
Ann Pharmacother; 2012; 46(7-8):960-71. PubMed ID: 22739715
[TBL] [Abstract][Full Text] [Related]
38. US Food and Drug Administration Black Box Warnings.
Smith RG
J Am Podiatr Med Assoc; 2020 Jan; 110(1):Article10. PubMed ID: 32073327
[TBL] [Abstract][Full Text] [Related]
39. Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: myocardial and infectious adverse reactions as application cases.
Wang K; Weng Z; Sun L; Sun J; Zhou SF; He L
Biochem Biophys Res Commun; 2015 Feb; 457(3):249-55. PubMed ID: 25576362
[TBL] [Abstract][Full Text] [Related]
40. Different black box warning labeling for same-class drugs.
Panagiotou OA; Contopoulos-Ioannidis DG; Papanikolaou PN; Ntzani EE; Ioannidis JP
J Gen Intern Med; 2011 Jun; 26(6):603-10. PubMed ID: 21286838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
